Dieter Scherer, PhD; Eva Alvarez-Gonzalez, PhD; and Anthony Pettigrew, MSc; examine a proprietary non-protic, aqueous-free ocular delivery system with the potential to provide an alternative approach in particular for poorly soluble drugs.
Frost & Sullivan Analysts Jennifer Brice and Deborah Toscano observe how the arrival of biosimilars, or highly similar copies of biopharmaceutical products, to the US market is imminent, and although they have been available elsewhere for several years, physicians and other key stakeholders in the US have only recently begun to anticipate their arrival.
FORMULATION DEVELOPMENT – KinetiSol: A New Processing Paradigm for Amorphous Solid Dispersion Systems
Dave A. Miller, PhD; James C. DiNunzio, PhD; Justin R. Hughey, PhD; Robert O. Williams III, PhD; and James W. McGinity, PhD; review how a novel fusion-based process for the production of amorphous solid dispersion systems has recently been adapted to pharmaceutical processing and is providing novel solutions for difficult-to-process compounds.
EXECUTIVE INTERVIEW – Novozymes Biopharma: Improving Drug Safety & Stability With Recombinant Human Albumin
Mark Perkins, Customer Solution Manager at Novozymes Biopharma, discusses how the company is improving the formulation of many new drugs and offering customers new ways of achieving a competitive advantage.
DRUG DELIVERY – Recent Advancements in Drug Delivery: Novel Formulations & Technologies Offer Improved Treatment Options
Debbie Toscano, Senior Industry Analyst, Frost & Sullivan, highlights a few recent innovative approaches to drug delivery with a focus on some of the therapeutic areas most relevant to the current pharmaceuticals market.
Gerallt Williams, PhD, takes a look at the market forces driving DPI innovation and focuses on a novel solution that has simplicity at the heart of its design, and which hopes to address the growing pressure to reduce healthcare costs, as well as the needs of new markets, arising from emerging economies in South America, India, and China.
Frost & Sullivan Analysts Winny Tan, PhD, and Jennifer Brice highlight two dynamic pharmaceutical service segments, CROs and IVD manufacturers, and how they are evolving to meet the growing preclinical and clinical trial needs of pharmaceutical companies. They also discuss open innovation models for outsourcing the earliest stage of drug discovery.
David M. Kleinman, MD; Andrew Loxley, PhD; Gillian M. Tocci, PhD; George Ngwa, PhD; William Gensheimer, MD; and Robert W. Lee, PhD; indicate PEGPLUS, a multifunctional graft copolymer, can be used in a host of topical ophthalmic applications.
EXCIPIENT UPDATE – Addressing Challenges With Low-Solubility Compounds: The Importance of Functional Excipients in the Formulation of Amorphous Dispersions
Rod Ray, PhD, explains that because more than half of the compounds in early development are considered poorly soluble, improving oral bioavailability represents a significant challenge to the pharmaceutical industry.
N.V. Satheesh Madhav, PhD, MPharm; and Pranshu Tangri, MPharm; formulate and evaluate sustained-release tablets of atorvastatin using a biomaterial isolated from unripe fruit pulp as a novel biobinder for the formulation of tablets.
EXCLUSIVE ONLINE CONTENT
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, recently announced a strategic partnership.
Medherant Limited, the clinical-stage developer of innovative transdermal delivery products for pain and CNS diseases using its unique TEPI Patch technology, recently announced a new $2.5-million investment.
Catalent (Booth 3101) recently announced it will launch its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologic drugs at the…
Cybrexa Therapeutics recently announced preclinical data supporting the potential of its proprietary alphalex technology platform.
HOOKIPA Pharma Inc. recently announced it has achieved a further research milestone in its collaboration and license agreement with Gilead Sciences, Inc. for development of a therapeutic hepatitis B virus (HBV) vaccine.